Clinical Trials Directory

Trials / Completed

CompletedNCT02003833

Poly-L-lactic Acid for Skin Quality

Randomized, Controlled, Multi-Centered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic) for Improving Facial Wrinkles and Skin Quality

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Sadick Research Group · Academic / Other
Sex
Female
Age
30 Years – 60 Years
Healthy volunteers
Accepted

Summary

Anecdotal evidence suggests that patients' skin quality may improve as a result of poly-L-lactic acid injection. While this is not the primary goal of such treatments it is often seen and described as so called "Sculptra glow". The aim of this study is to evaluate the effect of repeated subcutaneous injections of poly-L-lactic acid (Sculptra Aesthetic) on skin quality. Participating subjects will be part of the study for about 15 months. There will be an initial treatment period of up to 12 weeks, followed by a 12-month follow-up period. There will be a total of 7 scheduled visits. This study is a double-blind, randomized study. "Double-blind" means that neither the subjects nor the study doctor will know who is receiving Sculptra Aesthetic or placebo. "Randomized" means that the group subjects will be placed in is decided by chance, similar to drawing numbers out of a hat or flipping a coin. Subjects will have a 1 out of 2 chance of receiving the active study drug. After the completion of the study, if subjects are assigned to the control (placebo) group they will receive free injections with Sculptra Aesthetic same as the treatment group.

Conditions

Interventions

TypeNameDescription
DEVICEPoly-L-lactic acidSculptra injections
DEVICEPlacebo comparatorsaline injections

Timeline

Start date
2013-09-01
Primary completion
2015-03-01
Completion
2015-09-01
First posted
2013-12-06
Last updated
2015-11-20

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02003833. Inclusion in this directory is not an endorsement.